Evaluating only Nuvelo’s profile at its peak — without knowing the outcome — the model ranked Founder chaos as the #1 likely cause. Documented cause: No market fit.
Key Events Timeline
FOUNDING
Nuvelo founded
FUNDING
Nuvelo secures significant funding for Phase 3 clinical trials of alfimeprase
FRAUD EXPOSURE
Both pivotal Phase 3 trials for alfimeprase fail to meet primary endpoints; stock plummets 80% in single trading day
LAYOFF
Nuvelo cuts 70% of workforce following clinical trial failures and restructuring initiatives
ACQUISITION ATTEMPT
Nuvelo merges with ARCA biopharma in a distressed deal valuing the company at a fraction of its remaining cash position
SHUTDOWN
Silent Shutdown: Nuvelo ceases operations
Full Analysis
Free · no account needed
Documented cause
Nuvelo developed alfimeprase, a clot-dissolving agent for arterial occlusions, and alfimeprase for catheter occlusion clearance. The company invested heavily in two pivotal Phase 3 trials. In December 2006, both trials failed to meet primary endpoints. The stock dropped over 80 percent in one day. Nuvelo attempted restructuring, cut staff by 70 percent, and eventually merged with ARCA biopharma in 2008 in a deal that valued Nuvelo at a fraction of its cash position.
Lesson
“Biotech startups building on a single drug candidate are one Phase 3 readout away from extinction. Two simultaneous Phase 3 failures in the same compound eliminates every strategic alternative in 24 hours. Pipeline diversification is not just a strategy preference but a survival requirement when lead programs carry binary outcomes.”